FAST III Trial Confirms CAAS vFFR Non-Inferiority in Cardiology Procedures

The FAST III clinical trial results have confirmed that the angiography-based CAAS vFFR system is non-inferior to traditional invasive wire-based FFR. Conducted over a five-year period, the study evaluated the effectiveness of the software-based system in guiding coronary revascularization procedures. This validation provides a significant boost for Pie Medical Imaging, offering a less invasive alternative to traditional pressure wire methods for coronary assessments. The positive outcome is expected to accelerate the adoption of digital medical imaging solutions across the global healthcare sector. Furthermore, these results strengthen the market position of the Esaote Group within the competitive MedTech landscape. Industry experts suggest that shifting toward software-driven diagnostics could lower procedural risks and operational costs for cardiology departments.